MedTrace Logo

Cerebrospinal Fluid (CSF) Raltegravir Substudy

NCT00718029 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2019-08-13

No results posted yet for this study

Summary

The purpose of this study is to measure concentrations of Raltegravir in cerebrospinal fluid.

The hypotheses are:

* Raltegravir concentrations in CSF will be measurable
* Raltegravir concentrations in CSF will remain constant, while plasma concentrations vary widely leading to highly variable CSF-to-plasma ratios.
* Following at least 4 weeks of Raltegravir-containing combination therapy, HIV RNA levels in CSF will be below 50 copies/mL in all subjects.

Conditions

  • HIV Infections

Sponsors & Collaborators

Principal Investigators

  • Scott L Letendre, MD · University of California, San Diego AntiViral Research Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-07-31
Completion
2011-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00718029 on ClinicalTrials.gov